Imfinzi

ASCO: AstraZeneca guns for wider ovarian cancer market with Imfinzi-Lynparza combo. Will the FDA buy the plan?
ASCO: AstraZeneca guns for wider ovarian cancer market with Imfinzi-Lynparza combo. Will the FDA buy the plan?
Fierce Pharma
ASCO 2023
AstraZeneca
Lynparza
Imfinzi
ovarian cancer
Flag link:
AstraZeneca reports positive results from endometrial cancer therapy trial
AstraZeneca reports positive results from endometrial cancer therapy trial
Clinical Trials Arena
AstraZeneca
endometrial cancer
clinical trials
Imfinzi
Lynparza
Flag link:
AstraZeneca's drug combo shows positive results in late-stage cancer trial
AstraZeneca's drug combo shows positive results in late-stage cancer trial
Reuters
ASCO 2023
AstraZeneca
Imfinzi
Lynparza
endometrial cancer
Flag link:
AACR: AstraZeneca offers first look at Imfinzi's resectable lung cancer showing, fueling a key debate
AACR: AstraZeneca offers first look at Imfinzi's resectable lung cancer showing, fueling a key debate
Fierce Pharma
AstraZeneca
AACR
Imfinzi
non-small cell lung cancer
Flag link:
AstraZeneca's Lynparza-Imfinzi combo clears PhIII trial in ovarian cancer
AstraZeneca's Lynparza-Imfinzi combo clears PhIII trial in ovarian cancer
Endpoints
AstraZeneca
Lynparza
Imfinzi
ovarian cancer
clinical trials
Flag link:
AstraZeneca says cancer drug Imfinzi improves survival chances in late-stage trial
AstraZeneca says cancer drug Imfinzi improves survival chances in late-stage trial
Reuters
AstraZeneca
Imfinzi
lung cancer
Flag link:
Despite Imfinzi fail in lung cancer trial, AZ 'encouraged' by one result: exec
Despite Imfinzi fail in lung cancer trial, AZ 'encouraged' by one result: exec
Fierce Pharma
AstraZeneca
Imfinzi
lung cancer
non-small cell lung cancer
Flag link:
AstraZeneca: FDA Approves Imfinzi Plus Chemotherapy To Treat Biliary Tract Cancer
AstraZeneca: FDA Approves Imfinzi Plus Chemotherapy To Treat Biliary Tract Cancer
NASDAQ
AstraZeneca
Imfinzi
biliary tract cancer
FDA
Flag link:
AstraZeneca, chasing immunotherapy rivals, claims study success in early lung cancer
AstraZeneca, chasing immunotherapy rivals, claims study success in early lung cancer
BioPharma Dive
AstraZeneca
Imfinzi
clinical trials
non-small cell lung cancer
Flag link:
Here's What AstraZeneca's Recent FDA News Means for Shareholders
Here's What AstraZeneca's Recent FDA News Means for Shareholders
Motley Fool
AstraZeneca
FDA
Imfinzi
tremelimumab
liver cancer
Flag link:
AZ eyes Q3 FDA decision for Imfinzi in biliary tract cancer
AZ eyes Q3 FDA decision for Imfinzi in biliary tract cancer
Pharmaforum
AstraZeneca
Imfinzi
biliary tract cancer
FDA
priority review
Flag link:
AstraZeneca faces $278M Imfinzi patent infringement lawsuit from co-developer Ono
AstraZeneca faces $278M Imfinzi patent infringement lawsuit from co-developer Ono
Fierce Pharma
AstraZeneca
Ono Pharmaceutical
lung cancer
patents
Imfinzi
Flag link:
AZ’s Imfinzi is first immunotherapy to raise survival in biliary tract cancer
AZ’s Imfinzi is first immunotherapy to raise survival in biliary tract cancer
Pharmaforum
AstraZeneca
Imfinzi
biliary tract cancer
clinical trials
Flag link:
AstraZeneca: Imfinzi Plus Tremelimumab Improves OS In Phase III Trial In Liver Cancer
AstraZeneca: Imfinzi Plus Tremelimumab Improves OS In Phase III Trial In Liver Cancer
NASDAQ
AstraZeneca
liver cancer
clinical trials
Imfinzi
tremelimumab
Flag link:
ESMO 2021 – Astra coasts towards a new lung cancer combo
ESMO 2021 – Astra coasts towards a new lung cancer combo
EP Vantage
ESMO
AstraZeneca
Imfinzi
oleclumab
Innate Pharma
non-small cell lung cancer
Flag link:
AstraZeneca touts Imfinzi immunotherapy combos for lung cancer in push to drive PD-L1 drug uptake
AstraZeneca touts Imfinzi immunotherapy combos for lung cancer in push to drive PD-L1 drug uptake
Endpoints
AstraZeneca
Imfinzi
lung cancer
Flag link:
AstraZeneca earns another approval in jam-packed Chinese PD-(L)1 market, this time in late-stage lung cancer
AstraZeneca earns another approval in jam-packed Chinese PD-(L)1 market, this time in late-stage lung cancer
Endpoints
AstraZeneca
China
Imfinzi
Flag link:
#ASCO21: AstraZeneca's PD-1 Imfinzi tacks on 5-year survival data in NSCLC, which it's calling 'unprecedented'
#ASCO21: AstraZeneca's PD-1 Imfinzi tacks on 5-year survival data in NSCLC, which it's calling 'unprecedented'
Endpoints
ASCO 2021
AstraZeneca
non-small cell lung cancer
Imfinzi
Flag link:
Despite Imfinzi, US accelerated approvals surge
Despite Imfinzi, US accelerated approvals surge
EP Vantage
FDA
accelerated approvals
Imfinzi
AstraZeneca
Flag link:
AZ withdraws Imfinzi in US bladder cancer use after trial failure
AZ withdraws Imfinzi in US bladder cancer use after trial failure
Pharmaforum
AstraZeneca
Imfinzi
bladder cancer
metastatic bladder cancer
clinical trials
Flag link:

Pages